~~<i id='E31F147158'><strike id='E31F147158'><tt id='E31F147158'><pre id='E31F147158'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-10-02 00:11:03 Page View：1668

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages' outsize impact on ovarian cancer patients
Next article： In Memoriam: Notable people who died in 2023

leisure time

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

CMS got Medicare Advantage quality rating wrong, judge rules

AdobeThefederalgovernmentinappropriatelyloweredthe2024MedicareAdvantagestarratingsofSCANHealthPlan,w

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

The most pressing bird flu mysteries scientists want answered

Illustration:ChristineKao/STAT;Photos:Getty,Adobe,AP,CDCandNIAIDTenweeksaftergovernmentscientistsdis